More about

Osimertinib

News
June 15, 2020
2 min watch
Save

VIDEO: ADAURA trial ‘paradigm-shifting’ for lung cancer precision medicine

VIDEO: ADAURA trial ‘paradigm-shifting’ for lung cancer precision medicine

In this video, Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson Cancer Center, shares his perspective on the results from the ADAURA trial, a “potentially paradigm-shifting phase 3 study.”

News
June 08, 2020
3 min watch
Save

VIDEO: ASCO Plenary gives new data on adjuvant osimertinib

VIDEO: ASCO Plenary gives new data on adjuvant osimertinib

In this video, Julia K. Rotow, MD, medical oncologist at the Dana-Farber Cancer Institute, discusses presentations in lung cancer from the virtual ASCO annual meeting.

News
June 08, 2020
3 min watch
Save

VIDEO: ASCO 2020 ‘incredibly exciting’ for lung cancer data

VIDEO: ASCO 2020 ‘incredibly exciting’ for lung cancer data

In this video, Nathan A. Pennell, MD, PhD, medical oncologist at the Cleveland Clinic and associate professor medical oncology at the Cleveland Clinic Lerner College, discusses presentations in lung cancer that he found interesting from this year’s virtual ASCO Annual Meeting.

News
May 29, 2020
6 min read
Save

Adjuvant osimertinib extends DFS in EGFR-mutated NSCLC

Adjuvant osimertinib extends DFS in <i>EGFR</i>-mutated NSCLC

Adjuvant osimertinib significantly prolonged DFS for patients with EGFR-mutated non-small cell lung cancer, according to results of the randomized phase 3 ADAURA trial scheduled for presentation during the ASCO20 Virtual Scientific Program.

News
April 13, 2020
1 min read
Save

Adjuvant osimertinib shows ‘overwhelming efficacy’ for EGFR-mutated lung cancer

Adjuvant osimertinib shows &lsquo;overwhelming efficacy&rsquo; for <i>EGFR</i>-mutated lung cancer

Osimertinib demonstrated “overwhelming efficacy” for the adjuvant treatment of patients with stage IB, II and IIIA epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection, according to a press release issued by the agent’s manufacturer.

News
November 21, 2019
5 min read
Save

Osimertinib improves OS in untreated, advanced NSCLC

Osimertinib improves OS in untreated, advanced NSCLC

First-line osimertinib improved OS compared with standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors among patients with previously untreated advanced EGFR-mutated non-small cell lung cancer, according to results from the randomized phase 3 FLAURA trial presented at European Society for Medical Oncology Asia Congress and simultaneously published in The New England Journal of Medicine.

News
November 04, 2019
1 min read
Save

10 important updates for Lung Cancer Awareness Month

Lung Cancer Awareness Month — observed every November — is intended to educate the public about the potential causes and risk factors of the disease.

News
September 28, 2019
3 min read
Save

Front-line osimertinib improves OS in EGFR-mutated lung cancer

BARCELONA, Spain — Osimertinib significantly extended OS compared with standard epidermal growth factor receptor tyrosine kinase inhibitors as front-line treatment for EGFR-mutated advanced non-small cell lung cancer, according to late-breaking results of the randomized phase 3 FLAURA study presented at European Society for Medical Oncology Congress.

View more